All In Biotech

Drug Trial Radar · NCT06430385

ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)

A Phase 1-2, Double-Blind, Sham-Controlled Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Patients With MECP2 Duplication Syndrome

Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Oct 21, 2024

Primary completion

Sep 2027

Study completion Apr 2030

Sponsor

Lead sponsor
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
Sponsor type
Industry
First posted
May 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 2 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the safety and tolerability of ION440.

Conditions

  • Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome

Interventions

  • ION440Drug

    ION440 will be administered by intrathecal bolus (ITB) injection.

  • Sham procedureProcedure

    An LP will be performed with CSF collection but will not be followed by the administration of study treatment by ITB injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to approximately 36 weeks
  2. Part 1: Number of Participants With Clinically Significant Change From Baseline in Vital SignsTime frame: Baseline up to approximately 36 weeks
  3. Part 1: Number of Participants With Clinically Significant Change From Baseline in Physical and Neurological Examination FindingsTime frame: Baseline up to approximately 36 weeks
  4. Part 1: Number of Participants With Clinically Significant Change from Baseline in Laboratory AssessmentsTime frame: Baseline up to approximately 36 weeks
  5. Part 1: Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG)Time frame: Baseline up to approximately 36 weeks
  6. Part 2: Number of Participants With TEAEsTime frame: Up to approximately 192 weeks
  7. Part 2: Number of Participants With Clinically Significant Change From Baseline in Vital SignsTime frame: Baseline up to approximately 192 weeks
  8. Part 2: Number of Participants With Clinically Significant Change From Baseline in Physical and Neurological Examination FindingsTime frame: Baseline up to approximately 192 weeks
  9. Part 2: Number of Participants With Clinically Significant Change from Baseline in Laboratory AssessmentsTime frame: Baseline up to approximately 192 weeks
  10. Part 2: Number of Participants With Clinically Significant Change From Baseline in ECGTime frame: Baseline up to approximately 192 weeks

Locations

12 sites in 5 countries. Site status is shown where the registry gives one.

  • Rady Children's Hospital

    San Diego, California · Recruiting

  • University of Colorado Hopsital - Anschutz Medical Campus

    Aurora, Colorado · Recruiting

  • Kennedy Krieger

    Baltimore, Maryland · Recruiting

  • Boston Children's Hospital

    Boston, Massachusetts · Recruiting

  • Gillette Children's Specialty Healthcare

    Saint Paul, Minnesota · Recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • Baylor College of Medicine

    Houston, Texas · Recruiting

  • Kepler University Hospital

    Linz, Austria · Recruiting

  • British Columbia Children's Hospital

    Vancouver, Canada · Recruiting

  • CHU Dijon Bourgogne

    Dijon, France · Recruiting

  • Hospital Saint Joan de Deu

    Barcelona, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.